Download from app store
We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
Published in Dermatology

News · May 19, 2023

Brepocitinib Beneficial for Moderate-to-Severe Psoriatic Arthritis

Significantly greater ACR20 response rates seen at week 16 for 30 and 60 mg QD versus placebo; response maintained or improved at 52 weeks



Further Reading